Literature DB >> 7043067

Connective tissue components of the normal and fibrotic human liver. II. Clinical aspects.

G Pott, J Rauterberg, B Voss, U Gerlach.   

Abstract

In this second part, clinical aspects of connective tissue metabolism in the liver will be described and two main aspects considered. The first is the possibility to monitor the activity of fibrosis by the use of metabolites and enzymes of connective tissue metabolism. In recent studies the qualification for this purpose of enzymes such as procollagen prolyl hydroxylase and lysosomal N-Acetyl-beta-glucosaminidase and the N-terminal peptide of procollagen type III has been tested. The serum activities or concentrations of these substances in patients with chronic active liver diseases increase in due relation to the histologically estimated activity of liver fibrosis. The second aspect deals with therapeutic approaches to fibrosis in the liver by using connective tissue specific agents. So far none of the antifibrotic substances such as proline analogues, colchicine, lathyrogens and penicillamine has been used in longer-term antifibrotic treatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7043067     DOI: 10.1007/bf01721581

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  52 in total

1.  The rate of synthesis of glycosaminoglycans and collagen by fibroblasts cultured from adult human liver biopsies.

Authors:  J T Galambos; M A Hollingsworth; A Falek; W D Warren; J R McCain
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

2.  [Prolyl hydroxylase activity in liver specimens in chronic liver diseases (author's transl)].

Authors:  U Langness; H Clausnitzer; M Verspohl; K Grasedyck
Journal:  Med Klin       Date:  1978-08-25

3.  Primary cultures of rat hepatocytes synthesize fibronectin.

Authors:  B Voss; S Allam; J Rauterberg; K Ullrich; V Gieselmann; K von Figura
Journal:  Biochem Biophys Res Commun       Date:  1979-10-29       Impact factor: 3.575

4.  [Catabolic mucopolysaccharide metabolism in liver diseases].

Authors:  D Platt; B Leinweber
Journal:  Acta Hepatosplenol       Date:  1969 Sep-Oct

5.  [Diagnostic parameter of collagen biosynthesis].

Authors:  E G Hahn; G A Martini
Journal:  Internist (Berl)       Date:  1980-04       Impact factor: 0.743

6.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

Authors:  W H Summerskill; M G Korman; H V Ammon; A H Baggenstoss
Journal:  Gut       Date:  1975-11       Impact factor: 23.059

7.  Serum concentration of procollagen-III-peptide in comparison with the serum activity of N-acetyl-beta-glucosaminidase for diagnosis of the activity of liver fibrosis in patients with chronic active liver diseases.

Authors:  W Ackermann; G Pott; B Voss; K M Müller; U Gerlach
Journal:  Clin Chim Acta       Date:  1981-05       Impact factor: 3.786

8.  Prolyl hydroxylase activity in normal and diseased human liver.

Authors:  G C Fuller; J C Nolan
Journal:  Proc Soc Exp Biol Med       Date:  1976-01

9.  Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin.

Authors:  E Hahn; G Wick; D Pencev; R Timpl
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

10.  Rapid determination of fibronectin by laser nephelometry. Fibronectin concentrations is plasma in human diseases, I.

Authors:  G Pott; M Meyering; B Voss; H E Karges; A Sieber
Journal:  J Clin Chem Clin Biochem       Date:  1980-12
View more
  2 in total

1.  Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.

Authors:  D Y Lin; C M Chu; I S Sheen; Y F Liaw
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

2.  Long term treatment of severe obesity: four year follow up of results of combined behavioural modification programme.

Authors:  H Björvell; S Rössner
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.